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Abstract
Background: Induction of clelayed-type hypersensitivity has recently been in­
troduced for resistant viral warts. The method is not painful and less destructive 
than most other modalities. Objective: We assessed the efficacy of topical di­
phencyprone (diphenylcyclopropenone) treatment for recalcitrant warts. Meth­
ods: From September 1988 to June 1995, 134 patients with periungual and/or 
palmoplantar warts were entered into the study. Eight weekly applications were 
delivered. Results: The scheduled treatment course and follow-up were com­
pleted by 111 patients. There were 49 complete and 18 partial remissions. The 
rate of positive responders (60%) compares with the results published by other 
authors. Conclusion: Diphencyprone is an effective treatment for resistant 
warts, especially in palmoplantar and periungual locations.
Contact immunotherapy for resistant warts has been 
used since 1973 when Lewis [1] reported promising results 
with dinitrochlorobenzene. Later, Wiesner-Menzel and 
Happle [2] introduced diphenylcyclopropenone (diphency­
prone) for this purpose. Encouraging cure rates have been 
published [3-5], We studied the effect of diphencyprone in 
134 patients with refractory palmoplantar and periungual 
warts.
Patients and Methods
From September 1988 to June 1995, 134 patients with resistant 
warts participated in an open study o f  topical diphencyprone at the 
Department o f  Dermatology of the Sint Anna Hospital in Oss, The 
Netherlands. The patients comprised 53 males and 81 females, and 
were between 15 and 71 years of age. All but 8 patients had been
treated previously with curettage, cryotherapy, electrosurgery and/or 
keratolytics, without satisfactory result. The majority o f  patients had 
had their warts for over 1 yean
Patients were sensitized on the right upper arm with a 1% or 3% 
diphencyprone solution. If after 2 weeks no sensitization had o c ­
curred, diphencyprone was reapplied to the test site. When sensitiza­
tion had occurred, a diphencyprone solution o f  0 .1 -3%  was applied to 
the warts. Depending on the severity o f  the inflammatory reaction, a 
stronger or weaker solution was used at subsequent visits. The se ­
quence o f  concentrations used was 0.001, 0.003, 0 .01 ,0 .03 ,0 .1 ,  0.3, 
and 3 %.
Treatments were carried out once a week for 8 weeks, irrespective 
o f  the response, applications were then discontinued. Patients were 
followed after 2 and 4  months. Responses were defined as complete  
remission, partial remission (at least 50% overall regression) and no 
response (less than 50% regression, stable disease or progression).
Only patients over 15 years o f  age were included. Informed con­
sent was obtained. For those 15-18 years o f  age, also the parents gave  
consent.
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Table 1. Treatment results (percentage in parentheses) Discussion
Al end o f  treatment 
schedule
After 4  months
o f  follow-up
No response 
Partial remission  
Complete remission
47 (42) 
55 (50) 
9 (8 )
44 (39) 
18(16)  
49 (44)
One-lumdrecl-thirty-four patients were selected for the study. O f  
these, 1 ! were excluded for various reasons: unable to sensitize (2), 
spontaneous resolution o f  warts before first treatment (3), protocol vi­
olation (4) and misdiagnosis (2). Eleven patients did not complete the 
entire treatment series o f  8 weekly applications for the following rea­
sons: severe allergic reactions (5), disappointment in treatment results 
(5) or unknown reason (1). Thus 112 cases remained for evaluation.
Preliminary results of the treatment of 53 of these 
patients have been reported previously [6]. The present 
extended series confirms our earlier findings. The herein 
reported results compare with other studies so far [2-5], 
Diphencyprone appears to be an excellent modality to treat 
refractory warts. The method is not painful and less de­
structive than most other wart treatments. Diphencyprone is 
chemically stable when stored in dark bottles, has no seri­
ous side effects, is not mutagenic in the Ames test and is 
economical. Treatment, however, is time consuming.
The exact mode of action of diphencyprone treatment is 
unknown. Contact immunotherapy may work by the induc­
tion of a delayed-type hypersensitivity reaction. The im­
munological mechanism is probably a nonspecific cell-me­
diated immune response, triggering virus-infected cell lysis
The follow-up at 2  and 4  months was nearly complete (111/112; 99%). an d  d eath .
Results
Thus far, this is the largest follow-up series of wart pa­
tients treated with diphencyprone. Worthy of note is the ob­
servation, not mentioned in earlier reports, that many pa­
tients who exhibit partial involution of their warts at the end 
At the end of the treatment period, only 9 patients of the 8-week schedule notice further regression during the 
showed a complete remission. In 3 of them, treatment was months thereafter. This may have important implications 
discontinued before the end of the treatment scheme, after with regard to the treatment period and the frequency of ap-
2, 5 and 6 applications, respectively, because of complete plications. From our experience we have now modified the 
involution of the warts. Partial remissions were encoun- treatment course for our patients. Weekly applications for
tered in 55 patients. 10 weeks are scheduled. If the warts disappear entirely
During the follow-up period, the number of complete within 10 weeks, treatment is discontinued. In case of no
remissions increased to 49, Partial remissions were seen regression at all, treatment is also ceased. If partial regres-
in 18 cases. Sixteen patients with incomplete remission of sion is noticed, treatments are continued at fortnightly in-
their warts after 2-month follow-up experienced complete tervals for another 8 weeks. This treatment regimen is
remission after 4 months of follow-up. slightly more elaborate than the one used in this study but
The overall response rate (partial and complete remis- promises to be more yielding.
sions combined) at the end of the investigation was 60% 
(67/111). Table 1 shows an overview of our findings.
Naylor et al. [3] used daily treatments carried out by the 
patients themselves. Like Orecchia et a l [4], we did not
Side effects were not a problem in the majority of pa- allow patients to apply diphencyprone at home. We regard 
tients. Adverse effects included unusually severe reactions weekly applications as sufficient. Any delayed-type hyper- 
at the sensitization site or at the treatment site, or spreading sensitivity reaction will have its zenith within 24-72 h and
of contact eczema to other parts of the body.
We also studied risk markers for the outcome of diphen-
will last for at least 1 week.
Diphencyprone is an experimental drug. It is not com-
cyprone treatment. No statistically significant differences mercially available. Patients must be properly in formed and 
were observed when comparing subsets of patients accord- consent must be obtained. So far, no untoward long-term 
ing to gender, persistence of warts before entering the effects have been reported. Diphencyprone seems to be a 
study, site and number of warts or severity of eczematous safe and appropriate addition to our armament against re­
reactions at the sensitization and treatment sites. Only age calcitrant viral warts, 
of the patient had an effect on the remission rate. In those 
younger than 25 years, there were 44/59 remissions (75%) 
versus 23/52 (44%) in those 25 years or older (p = 0.001,
X2  test).
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N E R V A L ’ S D I A R Y
Le voyageur enthousiaste observe ...
Island of'Kos -  The place of Hippocrates, venue of the 35th 
Congress of the International Society for the History of
* Medicine (ISHM), September 2-8, 1996
|if| -  nil nocere
The oldest and central dogma of our profession is said to have origi­
nated here -  an appropriate setting for this meeting which cclcbrntcs the 
75th anniversary of the ISHM’s foundation. Originally planned for 1914, 
the foundation had to await the end of the First World War in Europe to be 
established. Today it comprises the representatives of 64 countries, alto­
gether some 700-odd members; attendees of 49 countries made it to Kos,
Kos -  an island in the sun, an amiable and amicable place* harboring 
the so-called plane tree of Hippokrates, the Asklepieion and many more 
witnesses of the ancient world. All lovingly preserved by the Greeks. But 
due to the nature and the history of the ISHM, a meeting not without innate 
problems, seen at least by a clinician who is accustomed to the American 
type of razor-sharp guidelines for congress programs and their setting into 
practice, the up-to-the-minute schedules, the one-language uniformity and 
efficiency.
National heritages must be preserved and recently I have engaged my­
self in stimulating readership of the A fmales and the Ha lit ant. Interna­
tional congresses must have but one language otherwise communication is 
impeded, and exchange across (speech) borders is what international con­
gresses are all about. The same principles apply to an international journal, 
e.g. the ISHM’s newly launched (and beautiful) VesaUus. Painful as it may 
be, some historical ballast will have to be dropped. The ISHM will have to 
learn this lesson or remain in the shadow of its competitors. And other­
wise? I have not been on a beach in the South of Europe for quite a time be­
cause of my complexion (phototype I). I am stunned to see how little our
message of sensible sun protection has come through. Thousands of square 
meters of European skin grilling in the sun, 12 h per day, a surprising 
percentage topless. Alas, clermaloheliosis with all ils manifestations of 
elastosis, keratoses, lentigines, spotty hypomelanosis, later cancers and 
melanomas can be foreseen. We will remain busy in the profession for 
some time to come.
At the end of the meeting, a ceremonial declamation of the Hippocratic 
oath was performed by actors in ancient costumes in the Asklepieion. 
Many of the physicians present raised their hands and joined in, myself in­
cluded. Therewith, I repeated my pledge after 36 years, in a sac red site, an 
unforgettable moment. It was September 7, for a Viennese dermatologist a 
hallowed date, Ferdinand Hebra’s 180th birthday.
Island of Patinas -  Place of one of the great visionaries of mankind, 
Sunday, September 8, 1996
To conclude my trip to the Aegean Sea, I visited the monastery of 
St. John the Divine. Compare it to what? Incomparable. But the memories 
of Bodhgaya, the place where Buddha was enlightened, flash through my 
mind. An equally unforgettable day.
rat etôa äXkov ayyekov 
ìoyvQÓv va KaTeßouvr] àrcó 
TÓv oi)Qavóv ••• Apocalypse X:1
à bientôt,
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